The role of growth factors in the development of diabetic nephropathy

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 4, 1996, Pages 322-329

  Hoffman, Brenda B ^a   Ziyadeh, Fuad N ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 1842580103     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199608000-00007     Document Type: Article

References (94)

1. Mogyorosi A, Ziyadeh FN: Update on pathogenesis, markers, and management of diabetic nephropathy. Curr Opin Nephrol Hypertens 1996, 5:243-253. A comprehensive review of current thoughts regarding mechanisms of diabetic nephropathy, clinical and genetic markers, and optimal guidelines for management.
2. LeRoith D, Werner H, Phillip M, Roberts CT: The role of insulin-like growth factors in diabetic kidney disease. Am J Kidney Dis 1993, 22:722-726.
3. Hammerman MR, Miller SB: The growth hormone insulin-like growth factor axis in kidney revisited. Am J Physiol 1993, 265:F1-F14.
4. Evan AP, Henry DP, Connors BA, Summerlin P, Lee W-H: Analysis of insulin-like growth factors (IGF)-I and -II, type II IGF receptor and IGF-binding protein-2 mRNA and peptide levels in normal and nephrectomized rat kidney. Kidney Int 1995, 48:1517-1529. The intrarenal distribution of IGF-I, IGF-II, type II IGF receptor, and IGFBP-2 is studied using in situ hybridization and immunocytochemistry.
5. Price GJ, Berka JL, Edmondson SR, Werther GA, Bach LA: Localization of mRNAs for insulin-like growth factor binding proteins 1 to 6 in rat kidney. Kidney Int 1995, 48:402-411. The heterogenous distribution of the IGFBP mRNAs in the kidney is described using in situ hybridization.
6. Conti FG, Striker LJ, Elliot SJ, Andereani D, Striker GE: Synthesis and release of insulinlike growth factor I by mesangial cells in culture. Am J Physiol 1988, 255:F1214-F1219.
7. Guler HP, Schmid C, Zapf J, Foresch ER: Effects of recombinant human insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci U S A 1989, 86:2868-2872.
8. Hirschberg R, Kopple JD, Blantz RC, Tucker BJ: Effects of recombinant human insulin-like growth factor I on glomerular dynamics in the rat. J Clin Invest 1991, 87:1200-1206.
9. Feld SM, Hirschberg R, Artishevsky A, Nast C, Adler SG: Insulin-like growth factor I induces mesangial proliferation and increases mRNA and secretion of collagen. Kidney Int 1995, 48:45-51.
10. Flyvbjerg A, Bornfeldt KE, Marshall SM, Arnqvist HJ, Orskov H: Kidney IGF-I mRNA in initial renal hypertrophy in experimental diabetes in rats. Diabetologia 1990, 33:334-338.
11. Cantanese VM, Sciavolino PJ, Lango MN: Discordant, organ-specific regulation of insulin-like growth factor-I messenger ribonucleic acid in insulin-deficient diabetes in rats. Endocrinology 1993, 132:496-503.
12. Werner H, Shen-Orr Z, Stannard B, Burbuera B, Roberts CT, LeRoith D: Experimental diabetes increases insulinlike growth factor I and II receptor concentration and gene expression in kidney. Diabetes 1990, 39:1490-1497.
13. Weiss O, Anner H, Nephesh I, Alayoff A, Bursztyn M, Raz I: Insulin-like growth factor-1 (IGF-I) and IGF-I receptor gene expression in the kidney of the chronically hypoinsulinemic rat and hyperinsulinemic rat. Metabolism 1995, 44:982-986. Glucose levels are shown to play an important role in the regulation of IGF-I receptor gene expression in the chronically diabetic rat.
14. Oamar BS, Foellmer HG, Hodgdon-Anandan L, Rosenzweig SA: Regulation of insulin-like growth factor-I receptors in diabetic mesangial cells. J Biol Chem 1991, 266:2369-2373.
15. Muchaneta-Kubara EC, Sayed-Ahmed N, Besbas N, Zhang G, Cope GH, El Nahas AM: Experimental diabetic renal growth: role of growth hormone and insulin-like growth factor-I. Nephrol Dial Transplant 1994, 9:1395-1401.
16. Flyvbjerg A, Marshall SM, Frystyk J, Hansen KW, Harris AG, Orskov H: Octreotide administration in diabetic rats: effect on renal hypertrophy and urinary albumin excretion. Kidney Int 1992, 41:805-812.
17. Gronbaek H, Nielsen B, Osterby R, Harris A, Orskov H, Flyvbjerg A: Effect of octreotide and insulin on manifest renal and glomerular hypertrophy and urinary albumin excretion in long-term experimental diabetes in rats. Diabetologia 1995, 38:135-144. Treatment with octreotide (a somatostatin analogue) for 3 weeks following an untreated diabetic period of 3 or 6 months is unable to reduce renal hypertrophy or urinary albumin excretion.
18. Serri O, Beauregard H, Brazeau P, Abribat T, Lambert J, Harris A, Vachon L: Somatostatin analogue, octreotide, reduces increased glomerular filtration rate and kidney size in insulin-dependent diabetes. JAMA 1991, 265:888-892.
19. Chin E, Michels K, Bondy CA: Partition of insulin-like growth factor (IGF)-binding sites between the IGF-I and IGF-II receptors and IGF-binding proteins in the human kidney. J Clin Enocrinol Metab 1994, 78:156-164.
20. Grellier P, Sabbath M, Fouquery B, Woodruff K, Yee D, Abboud HE, Abboud SL: Characterization of insulin-like growth factor binding proteins and regulation of IGFBP-3 in human mesangial cells. Kidney Int 1996, 49:1071-1078.
21. Gelato MC, Alexander D, Marsh K: Differential tissue regulation of insulinlike growth factor binding proteins in experimental diabetes mellitus in the rat. Diabetes 1992, 41:1511-1519.
22. Bach LA, Cox AJ, Mendelsohn AO, Herington AC, Werther GA, Jerums G: Focal induction of IGF-I binding proteins in proximal tubules of diabetic rat kidney. Diabetes 1992, 41:499-507.
23. Kaufman CR, Catanese VM: Pre- and post-translational regulation of renal insulin-like growth factor binding protein-1 in insulin-deficient diabetes. J Invest Med 1995, 43:178-186. Data suggest that insulin strongly regulates pre- and posttranslational renal IGFBP-1 gene expression and implicate IGFBP-1 as an important determinant of IGF-I activity in the diabetic kidney.
24. Landau D, Chin E, Bondy C, Domene H, Roberts CT, Gronbaek H, Flyvbjerg A, LeRoith D: Expression of insulin-like growth factor binding proteins in the rat kidney: effects of long-term diabetes. Endocrinology 1995, 136:1835-1842. The regulation of IGFBP gene expression is quite complex in diabetes, with divergent changes in IGFBP-1 and -5 mRNA levels in the cortex versus the outer medulla.
25. Ooi GT, Tseng YH, Tran MQ, Rechler MM: Insulin rapidly decreases insulin-like growth factor-binding protein-I gene transcription in streptozotocin-diabetic rats. Mol Endocrinol 1992, 6:2219-2228.
26. DeRubertis FR, Craven PA: Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. Am J Kidney Dis 1993, 22:727-735.
27. Craven PA, DeRubertis FR: Role for local prostaglandin and thromboxane production in the regulation of glomerular filtration rate in the rat with streptozotocin-induced diabetes. J Lab Clin Med 1989, 113:674-681.
28. Esmatjes E, Fernandez MR, Halperin I: Renal hemodynamic abnormalities in patients with short term insulin-dependent diabetes mellitus: role of renal prostaglandins. J Clin Endocrinol Metab 1985, 60:1231-1236.
29. Craven PA, Melhem MF, DeRubertis FR: Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney Int 1992, 42:937-946.
30. Williams B, Schrier RW: Glucose-induced protein kinase C activity regulated arachidonic acid release and eicosanoid production by cultured glomerular mesangial cells. J Clin Invest 1993, 92:2889-2896.
31. Wilkes BM, Kaplan R, Mento PF, Aynedjian HS, Macica CM, Schlondorff O, Bank N: Reduced glomerular thromboxane receptor sites and vasoconstrictor responses in diabetic rats. Kidney Int 1992, 41:992-999.
32. Abe T, Takeuchi K, Takahashi N, Tsutsumi E, Taniyama Y, Abe K: Rat kidney thromboxane receptor: molecular cloning, signal transduction, and intrarenal expression localization. J Clin Invest 1995, 96:657-664. A functional rat kidney thromboxane receptor is cloned and is found to be expressed specifically in the glomerulus, arterial smooth muscle cells, and transitional cell epithelium.
33. Uriu K, Kaizu K, Hashimoto O, Komine N, Eton S: Acute and chronic effects of thromboxane A2 inhibition on the renal hemodynamics in streptozotocin-induced diabetic rats. Kidney Int 1994, 45:794-802.
34. Tajiri Y, Umeda F, Inoguchi T, Nawata H: Effects of thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandin excretion and renal function in streptozotocin-induced diabetic rat. J Diabetes Complications 1994, 8:126-132.
35. Matsuo Y, Takagawa I, Koshida H, Kawabata T, Nakamura M, Ida T, Zhou L, Marumo F: Antiproteinuric effect of a thromboxane receptor antagonist, S-1452, on rat diabetic nephropathy and murine lupus nephritis. Pharmacology 1995, 50:1-8.
36. Kontessis PS, Jones SL, Barrow SE, Stratton PD, Alessandrini P, Cosmo SD, Ritter JM, Viberti GC: Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy. J Lab Clin Med 1993, 121:415-423.
37. Negrete H, Studer RK, Craven PA, DeRubertis FR: Role for transforming growth factor beta in thromboxane-induced increases in mesangial cell fibronectin synthesis. Diabetes 1995, 44:335-339.
38. Studer RK, Negrete H, Craven PA, DeRubertis FR: Protein kinase C signals thromboxane induced increases in fibronectin synthesis and TGF-beta bioactivity in mesangial cells. Kidney Int 1995, 48:422-430. Findings in this study and the study by Negrete et al. (Diabetes 1995, 44:335-339) indicate that activation of PKC by a thromboxane analogue signals an increase in TGF-β production and bioactivity, which in turn stimulates fibronectin synthesis.
39. Craven PA, Studer RK, DeRubertis FR: Impaired nitric oxide-dependent cyclic guanosine monophosphate generation in glomeruli from diabetic rats. J Clin Invest 1994, 93:311-320.
40. Mahadevan P, Larkins RG, Fraser JRE, Fosang AJ, Dunlop ME: Increased hyaluronan production in the glomeruli from diabetic rats: a link between glucose-induced prostaglandin production and reduced sulphated proteoglycan. Diabetologia 1995, 38:298-305.
41. Abboud HE: Role of platelet-derived growth factor in renal injury. Annu Rev Physiol 1995, 57:297-309. This is an excellent, comprehensive review describing the biology of the PDGF system and its role in mediating renal disease. The role of PDGF and its receptors in renal development is also discussed.
42. Alpers CE, Johnson RJ: Growth factors and the glomerulus: relationships between development and injury. Adv Nephrol 1995, 24:33-52. This updated review describes the roles of PDGF, basic fibroblast growth factor, and neurotrophins in mediating renal disease. The hypothesis is raised that glomerular response to injury recapitulates normal developmental processes.
43. Nakamura T, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, Koide H: mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 1993, 42:450-456.
44. Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995, 47:935-944.
45. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M: PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int 1995, 48:111-117.
46. Doi TT, Vlassara H, Kirstein M, Yamada Y, Striker GE, Striker L: Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc Natl Acad Sci U S A 1992, 89:2873-2877.
47. Yang C-W, Vlassara H, Peten EP, He C-J, Striker GE, Striker LJ: Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A 1994, 91:9436-9440.
48. Wenzel UO, Fouqueray B, Bisvvas P, Grandaliano G, Choudhury GG, Abboud HE: Activation of mesangial cells by the phosphatase inhibitor vanadate: potential implications for diabetic nephropathy. J Clin Invest 1995, 95:1244-1252. This paper describes the undesirable activation of mesangial cells by vanadate, a possible therapeutic agent in diabetes mellitus that has insulinlike action.
49. Egido J: Vasoactive hormones and renal sclerosis. Kidney Int 1996, 49:578-597. This comprehensive review discusses the role of angiotensin II as a growth factor and the use of angiotensin-converting enzyme inhibitors and angiotensin II antagonists in renal disease.
50. Atiyeh BA, Arant BS Jr., Henrich WL, Seikaly MG: In vitro production of angiotensin II by isolated glomeruli. Am J Physiol 1995, 268:F266-272.
51. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462.
52. Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, Bertani T, Remuzzi G: Short and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993, 4:40-49.
53. Wolf G, Thaiss F: Hyperglycemia: pathophysiological aspects at the cellular level. Nephrol Dial Transplant 1995, 10:1109-1112.
54. Harris RC, Martinez-Maldonado M: Angiotensin II-mediated renal injury. Miner Electrolyte Metab 1995, 21:328-335.
55. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993, 3:1531-1540.
56. Nakamura T, Takahashi T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H: Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 1995, 5:1492-1497.
57. Wolf G, Mueller E, Stahl RAK, Ziyadeh FN: Angiotensin Ii-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous TGF-β. J Clin Invest 1993, 92:1366-1373.
58. Wolf G, Ziyadeh FN, Zahner G, Stahl RAK: Angiotensin II-stimulated expression of transforming growth factor-β1 in renal proximal tubular cells: attenuation after stable transfection with c-mas oncogene. Kidney Int 1995, 48:1818-1827.
59. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-b expression in rat glomerular mesangial cells. J Clin Invest 1994, 93:2431-2437.
60. Wolf G, Neilson EG, Goldfarb Z, Ziyadeh FN: The influence of glucose concentration on angiotensin II-induced hypertrophy of proximal tubular cells in culture. Biochem Biophys Res Commun 1991, 176:902-909.
61. Ling H, Vamvakas S, Schaefer L, Schnittler HJ, Schaefer RM, Heidland A: Angiotensin II-induced cellular hypertrophy: potential role of impaired proteolytic activity in cultured LLC-PK1 cells. Nephrol Dial Transplant 1995, 10:1305-1312.
62. Cheng HF, Burns KD, Harris RC: Reduced proximal tubule angiotensin II receptor expression in streptozotocin-induced diabetes mellitus. Kidney Int 1994, 46:1603-1610.
63. Ballerman BJ, Skorecki KL, Brenner BM: Reduced glomerular angiotensin II receptor density in early untreated diabetes mellitus in the rat. Am J Physiol 1984, 247:F110-F116.
64. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993, 265:F477-F486.
65. Kalinyak JE, Sechi LA, Griffin CA, Don BR, Tavanger K, Krasmer FB, Hoffman AR, Schambelan M: The renin-angiotensin system in streptozotocin-induced diabetes mellitus in the rat. J Am Soc Nephrol 1993, 4:1337-1345.
66. Cheng H-F, Becker BN, Burns KD, Harris RC: Angiotensin II upregulates type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest 1995, 95:2012-2019. A transfection approach is utilized to demonstrate the upregulation of proximal tubule angiotensin type I receptor expression by angiotensin II.
67. Hurst RD, Stevanovic ZS, Munk S, Derylo B, Zhou X, Moor J, Silverberg M, Whiteside CI: Glomerular mesangial cell altered contractility in high glucose is Ca2+ independent. Diabetes 1995, 44:759-766.
68. Arima S, Ito S, Omata K, Takeuchi K, Abe K: High glucose augments angiotensin II action by inhibiting NO synthesis in in vitro microperfused rabbit afferent arterioles. Kidney Int 1995, 48:683-689.
69. Ling BN, Seal EE, Eaton DC: Regulation of mesangial cell ion channels by insulin and angiotensin II: possible role in diabetic glomerular hyperfiltation. J Clin Invest 1993, 92:2141-2151.
70. Takahashi K, Ghatei MA, Lam H-C, O'Halloran DJ, Bloom SR: Elevated plasma endothelin levels in patients with diabetes mellitus. Diabetologia 1990, 33:306-310.
71. Ferri C, Laurenti O, Bellini C, Faldetta MRC, Properzi G, Santucci A, De Mattia G: Circulating endothelin-1 levels in lean non-insulin-dependent diabetic patients. Am J Hypertens 1995, 8:40-47.
72. Dohi Y, Hahn AW, Boulanger CM, Buhler FR, Luscher TF: Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992, 19:131-137.
73. Nakamura T, Ebihara I, Fukui M, Tomino Y, Koide H: Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995, 44:895-899. This paper provides provocative evidence for increased glomerular endothelins in the pathogenesis of matrix expansion in diabetic rats.
74. Sharma K, Ziyadeh FN: The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 1994, 266:F829-F842.
75. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
76. Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-beta as a key mediator. Diabetes 1995, 44:1139-1146. A detailed review of the evidence derived from cell culture and experimental animals linking the autocrine overproduction of TGF-β and diabetic renal disease. Mechanisms of upregulation of TGF-β in the diabetic kidney are discussed. Therapeutic approaches to attenuate TGF-β activity are also addressed.
77. Rocco M, Chen Y, Goldfarb S, Ziyadeh FN: Elevated glucose stimulates TGF-β gene expression and bioactivity in proximal tubule. Kidney Int 1992, 41:107-114.
78. Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN: High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int 1992, 42:647-656.
79. Phillips AO, Steadman R, Topley N, Williams JD: Elevated D-glucose concentrations modulate TGF-beta 1 synthesis by human cultured renal proximal tubular cells: the permissive role of platelet-derived growth factor. Am J Pathol 1995, 147:362-374.
80. Ziyadeh FN, Sharma K, Ericksen M, Wolf G: Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by activation of transforming growth factor-β. J Clin Invest 1994, 93:536-542.
81. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 1993, 90:1814-1818.
82. Sharma K, Ziyadeh FN: Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 1994, 267:F1094-2001.
83. Pankewycz OG, Guan JX, Bolton WK, Gomez A, Benedict JF: Renal TGF-beta regulation in spontaneously diabetic NOD mice with correlations in mesangial cells. Kidney Int 1994, 46:748-58.
84. Shankland SJ, Scholey JW: Expression of transforming growth factor-b1 during diabetic renal hypertrophy. Kidney Int 1994, 46:430-442.
85. Yang CW, Hattori M, Vlassara H, He CJ, Carome MA, Yamato E, Elliot S, Striker GE, Striker LJ: Overexpression of transforming growth factor-beta1 mRNA is associated with up-regulation of glomerular tenascin and laminin gene expression in nonobese diabetic mice. J Am Soc Nephrol 1995, 5:1610-1617.
86. Sharma K, Jin Y, Quo J, Ziyadeh FN: Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in streptozotocin-induced diabetic mice. Diabetes 1996, 45:522-530.
87. Yoshioka K, Takemura T, Murakami K, Okada M, Hino S, Miyamoto H, Maki S: Transforming growth factor-β protein and mRNA in glomeruli in normal and diseased human kidneys. Lab Invest 1993, 68:154-163.
88. Sharma K, McGowan T, Ziyadeh FN, Kurnik B, Kurnik P, Weisberg L: Renal production of TGF-β is increased in diabetic patients. J Am Soc Nephrol 1995, 6:455.
89. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishada A, Gold LI, Border WA: Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int 1996, 49:461-469. This important paper describes increased protein expression of all three TGF-β isoforms in a spectrum of glomerular disorders (including diabetic nephropathy) that are characterized by increased matrix deposition in the glomerular and interstitial compartments.
90. Iwano M, Kubo A, Nishino T, Sato H, Nishioka H, Akai Y, Kurioka H, Fujii Y, Kanauchi M, Shiiki H, Dohi K: Quantification of glomerular TGF-β1 mRNA in patients with diabetes mellitus. Kidney Int 1996, 49:1120-1126. An important study providing evidence of increased TGF-β1 mRNA levels in glomeruli from human biopsy material obtained from diabetic patients.
91. Haberstroh U, Zahner G, Disser M, Thaiss F, Wolf G, Stahl RA: TGF β1 stimulates rat mesangial cell proliferation in culture: role of PDGF β receptor expression. Am J Physiol 1993, 264:F199-F205.
92. Ziyadeh FN, Jin Y, Guo J, Ericksen M, Sharma K: Up-regulation of type II TGF-β receptor mRNA by IGF-1 in proximal tubular cells: role in diabetic renal hypertrophy [abstract]. J Am Soc Nephrol 1995, 6:1053.
93. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta analysis. Ann Intern Med 1996, 124:627-632.
94. Okuda S, Nakamura T, Yamamoto T, Ruoslahti E, Border WA: Dietary protein restriction rapidly reduces transforming growth factor-b1 expression in experimental glomerulonephritis. Proc Natl Acad Sci U S A 1991, 88:9765-9769.